CannaGrowth.com | GW Pharma aiming for FDA approval for CBD drug this year, again
28117
post-template-default,single,single-post,postid-28117,single-format-standard,ajax_fade,page_not_loaded,,vertical_menu_enabled,side_area_uncovered_from_content,qode-theme-ver-7.2,wpb-js-composer js-comp-ver-4.5.1,vc_responsive

GW Pharma aiming for FDA approval for CBD drug this year, again

26 Jan GW Pharma aiming for FDA approval for CBD drug this year, again

British cannabis company GW Pharmaceuticals is hoping the U.S. Food and Drug Administration will sign off on its CBD-based epilepsy treatment, Epidiolex, as soon as this year. According to The Washington Post, GW is hoping to get the green light from the FDA to classify Epidiolex as a prescription drug, despite the fact it’s derived […] GW Pharma aiming for FDA approval for CBD drug this year, again is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

The post GW Pharma aiming for FDA approval for CBD drug this year, again appeared first on InvestinCannabis.com.

No Comments

Sorry, the comment form is closed at this time.